First in human phase 1 dose escalation and expansion clinical trial to evaluate the safety, pharmacokinetics and antitumor activity of intravenous AROG4-01 in patients with advanced solid tumors.


Por: Macia, S, Valenti, V, Jove, M, Hierro, C, Moreno, V, Gil-Martin, M, Calvo, E, Nadal, E and Plasencia, C

Publicada: 1 jun 2025
Resumen:


Filiaciones:
Appl Res Using OMIC Sci, Barcelona, Spain
Hosp Santa Tecla, Tarragona, Spain
Hospitalet, Catalan Inst Oncol, Barcelona, Spain
Germans Trias i Pujol Univ Hosp, Catalan Inst Oncol ICO Badalona, Badalona, Spain
Hosp Fdn Jimenez Diaz, START Madrid FJD, Madrid, Spain
Catalan Inst Oncol ICO, Barcelona, Spain
Ctr Integral Oncol Clara Campal, START Madrid CIOCC, Madrid, Spain
Bellvitge Biomed Res Inst IDIBELL, Catalan Inst Oncol ICO, Dept Med Oncol, Barcelona, Spain
ISSN: 0732183X





JOURNAL OF CLINICAL ONCOLOGY
Editorial
American Society of Clinical Oncology, 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA, Estados Unidos America
Tipo de documento: Meeting Abstract
Volumen: 43 Número: 16_SUPPL
Páginas: 3176-3176
WOS Id: 001690279500039

MÉTRICAS